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Abstract
Malignant mixed Müllerian tumor is a rare malignancy of the genital tract and extremely uncommon in
extragenital sites. This report describes a case of malignant mixed Müllerian tumor arising in the lower peritoneum
of a 72-year-old female patient. The patient presented with ascites, lower abdominal mass and pleural effusion. The
serum level of CA125 was elevated. At operation a diffuse carcinosis associated with tumor mass measuring 20 ×
15 × 10 cm in the vesicouterine and Duglas’ pouch were found. The uterus and the adnexa were unremarkable.
Histopathology revealed a typical malignant mixed Müllerian tumor, heterologous type. The epithelial component
was positive for cytokeratin 7 and vimentin whereas the mesenchymal component was positive for Vimentin, S100
and focally for CK7. The histogenesis of this tumor arising from the peritoneum is still speculative. Based on the
previous reports and the immunohistochemical analysis of our case, we believe that this is a monoclonal tumor
with carcinoma being the “precursor” element. Nevertheless, further molecular and genetic evidence is needed to
support such a conclusion.
Background
Malignant mixed Müllerian tumor (MMMT) is a rare
entity that arises from structures that are embryologi-
cally related to the Müllerian system [1,2]. The usual
location of MMMT is the female genital tract. Extrage-
nital origin is extremely rare [3-5]. Histologically and by
immunohistochemistry, the tumor exhibits both epithe-
lial and mesenchymal components.
S i n c et h ef i r s tr e p o r ti n1 9 5 5b yO b e ra n dB l a c k[ 5 ] ,
to our knowledge there have been only 30 well docu-
mented reports of extragenital malignant mixed Müller-
ian tumors [6-15]. This prompted us to report on a
tumor with primary peritoneal location and to review
the relevant existing literature.
Case Report
A 72-year-old woman, with unremarkable gynaecological
history presented with chest pain and dyspnoea, increas-
ing in intensity over the last three weeks. A chest X-ray
showed pleural effusion and the subsequent fine needle
aspiration cytology revealed malignant epithelial cells.
The serum level of CA125 was 712 U/ml.
CT scan of abdomen and chest revealed ascites and
pleural effusion but no tumor mass. Pelvic ultrasonogra-
phy, however, revealed excrescences adjacent to the
interior surface of the abdominal wall and tumor load in
the lower part of abdomen. The uterus and the right
ovary were described as normal; the left ovary was not
visualised.
An ultrasound-guided biopsy from the tumor reported
a carcinosarcoma (see later).
The patient underwent exploratory laparotomy. A
widely spread peritoneal carcinosis and a tumor measur-
i n g2 0×1 5×1 0c mi nt h ev e s i c o u t e r i n ea n dD u g l a s ’
pouch were found.
Biopsy samples were taken from the tumor as well as
from the serosa of the urinary bladder. Also, complete
hysterectomy with partial omentectomy was performed.
There was no suspicion of intrahepatic metastasis. Gall-
bladder, stomach, pancreas and appendix were
unremarkable.
Histopathology was consistent with the diagnosis of a
primary peritoneal malignant mixed Müllerian tumor
given that the uterus and the adnexa were unremarkable.
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(Carboplatin in doses of 468 mg/360 mg every third
week, as it was not felt that the patient was fit for more
aggressive treatment). The disease progressed despite
treatment and subsequent introduction of Treosulfan.
The patient passed away 12 months after diagnosis.
No autopsy was performed.
Material and methods
Gross pathology
The tumor tissue submitted for pathology were frag-
mented, irregular tissue masses measuring altogether 16
× 12 × 4.5cm. All the fragments were tan-white, irregu-
lar fleshy masses with areas of necrosis and hemorrhage.
The uterus and the Fallopian tubes were unremark-
able. The right and the left ovary were of normal dimen-
sions. Numerous sections were taken from the tumor as
well as from the uterus and adnexa.
Histology and Histochemistry
The tissue was fixed in 10% neutral buffered formalin
(pH 7,0), routinely processed, and embedded in paraffin
using standard methods. Four-micrometer sections were
stained with hematoxylin and eosin, Periodic acid-Schiff
(PAS) with diastase predigestion, and Alcian/PAS.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was stained
with the peroxidase method using the EnVision visuali-
sation system (Additional file 1).
Results
Histology and histochemistry
Most of the tumor tissue had the characteristics of poorly
differentiated carcinoma (Figure 1). There was no
squamous cell or glandular differentiation. The mesench-
ymal component was composed of sheets of undifferen-
tiated spindle cells and areas of cartilage (Figure 2).
Numerous sections from theu t e r u sa n dt h ea d n e x a e
showed no evidence of tumor.
Immunohistochemistry
Immunohistochemical staining for cytokeratin 7 deco-
rated cells of the epithelial component and scattered
cells within the mesenchymal component (Figure 3 and
Figure 4). Vimentin was strongly positive in mesenchy-
mal component and sporadicaly in the epithelial areas
(Figure 5). Cytokeratin 20 and calretinin were negative
in both epithelial and mesenchymal elements.
Discussion and the review of Literature
Malignant mixed Müllerian tumor (MMMT) is a
highly aggressive tumor consisted of malignant
Figure 1 Histological picture showing the admixed carcinoma
and spindle cell sarcomatous elements (HE × 200).
Figure 2 Histological picture showing malignant cartilage
admixed with sheets of undifferentiated spindle cells (HE ×
400).
Figure 3 Immunohistochemical stain with Cytokeratin 7 shows
strong immunoreactivity of the undifferentiated epithelial cells
(× 400).
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regarded as a subtype of uterine sarcomas or a mixture
of true carcinoma and sarcoma, however several
reports suggested a monoclonal origin of these tumors
[1-3] Interestingly, molecular data published by Wada
and co-workers [4] suggested that although most carci-
nosarcomas are combination tumors, some develop as
collision tumors.
The morphology of the present tumor is consistent
with malignant mixed Müllerian tumor. The epithelial
component exhibited positivity for cytokeratin 7 and
Vimentin and was negative for Cytokeratin 20. More-
over, the mesenchymal component was diffusely positive
for Vimentin, focally for CK 7 and exhibited areas of
heterologous malignant cartilage.
The primary peritoneal location and origin was con-
firmed after thorough gross and microscopic
examination of the uterus and adnexae. Furthermore,
absence of calretinin expression suggested that the
tumor was of Müllerian rather than pure mesothelial
origin [6]. A search of the literature revealed 30 pre-
viously reported cases of extragenital MMMT (Addi-
tional file 2) with the majority of the patients being in
the postmenopausal age [5-19]. Twenty-two of the
reported cases were of primary peritoneal origin and
most of them arose in the pelvis [19]. Thirteen were
heterologous type [19].
In the homologous type MMMT, mesothelioma would
rightfully be considered as a possibility [6]. However, in
this case a positive reaction of the cells to Calretinin
would be expected [6]. Immunoreactivity of the epithe-
lial cells to Cytokeratin 7 and negative reaction for cyto-
keratin 20 also points toward Müllerian origin. A
theoretical possibility is of course the origin in endome-
triosis or endosalpingiosis. However, although impossi-
ble to rule out, the lack of demonstrable endometriosis
associated with the patient’s current tumor makes this
hypothesis unlikely [16].
Several theories have emerged in the attempt to
explain the biphasic appearance of the tumor, the most
important of which are the “collision”, “conversion” and
the “combination” theory [1]. Sternberg et al. [20] was
the first to suggest the conversion, stating that sarcoma-
tous elements may develop from carcinoma. They
described a case of metastatic heterologous type carci-
nosarcoma of the omentum with primary endometrial
origin. There was no evidence of sarcoma component in
the primary tumor. From that time onward, a number
of cases with metachronous or synchronous gynaecolo-
gic carcinoma have been reported [11,14,16]. Masuda et
al. [21] further supported the conversion theory with
their study in which cell lines established from malig-
nant mixed Müllerian tumors showed the ability of the
epithelial tumor cells to transform into epithelial,
mesenchymal or both types of differentiation in vitro,
while the mesenchymal cells did not show similar
capabilities.
MMMT has a poor prognosis with most of the patients
following a rapidly fatal course regardless of the initial
tumor stage [9]. A review done by Garamvoelgyi et al. [14]
showed that most patients passed away within one year
with median postoperative survival time being 14 months.
Due to the rarity of the disease, limited data regarding the
management of peritoneal MMMT exist. Treatment mod-
alities include surgery, chemotherapy and irradiation with
various survival outcomes. Ko et al. [19] reported on a
patient that was treated with optimal tumor debulking and
a combination of chemotherapy with Ifosfamide and Cis-
platin, followed by pelvic irradiation. There were no signs
of recurrence for 48 months and was the case with the
longest disease-free survival in the reported literature.
Figure 5 Immunohistochemical stain with Vimentin shows
areas with strong immunoreactivity of the epithelial and
mesenchymal cells (× 400).
Figure 4 Immunohistochemical stain with Cytokeratin 7 shows
scattered Cytokeratin 7-positive cells in the mesenchymal
component (× 400).
Kurshumliu et al. World Journal of Surgical Oncology 2011, 9:17
http://www.wjso.com/content/9/1/17
Page 3 of 4Conclusion
Based on the ample evidence of the previous reports,
and the immunohistochemical analysis of our case, we
believe that this is a monoclonal tumor with the carci-
noma being the “precursor” element. Nevertheless,
further molecular and genetic evidence is needed to
support such a conclusion.
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